Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-15 fusion protein BJ-001
- Development stage
- Phase 1
- Lead developer
- BJ Bioscience
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BJ-001 is a first-in-class, tumor-targeting recombinant human interleukin-15 (IL-15) fusion protein. It is composed of an integrin-binding Arg-Gly-Asp (RGD)-4C motif linked to a human IgG1 Fc region, followed by a modified sushi domain of the human IL-15 receptor alpha (IL-15Rα) and human IL-15. The drug is designed to target tumors with integrin overexpression and stimulate immune responses via the IL-15 pathway. Its mechanism involves acting as an agonist at the interleukin 15 receptor subunit alpha, promoting natural killer (NK) cell proliferation while maintaining regulatory T cell stability. Developed by BJ Bioscience, it is being investigated primarily for cancer indications such as solid tumors and infectious diseases. As of early 2025, it has orphan drug designation for cholangiocarcinoma and has reached Phase 1 clinical trials in both oncology and infectious disease settings[1][3][4][5][8].
- Other names
- interleukin-15 fusion protein BJ-001interleukin15 fusion protein BJ-001interleukin 15 fusion protein BJ-001
02
Targets
αVβ3 (Integrin αVβ3)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on interleukin-15 fusion protein BJ-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-15 fusion protein BJ-001.